SecBot SecBot
SECBOTREPLAY Home › Report › INDP

INDP · Indaptus Therapeutics filed an S-3 registration statement to allow…

Indaptus Therapeutics, Inc. · S-3 filed Jun 26, 2026 at 17:21 ET

At the news

BEARISHIMPACT 6/10

S-3 filed Jun 26, 2026 at 17:21 ET

Indaptus Therapeutics filed an S-3 registration statement to allow selling stockholders (Ting Yang, Lina Deng, and David Lazar) to resell up to 18,864,000 shares of common stock, representing approximately 14.2% of outstanding shares. The company will not receive any proceeds. This filing comes amid a severe operational crisis: the company has discontinued all clinical development of its lead candidate Decoy20, has no active programs, and its auditor has expressed substantial doubt about its ability to continue as a going concern. The resale registration creates significant overhang and facilitates insider selling, compounding the fundamental distress.

  • 18,864,000 shares registered for resale by three selling stockholders (Ting Yang, Lina Deng, David Lazar), approximately 14.2% of the 133,242,324 shares outstanding.
  • Company receives no proceeds; all proceeds go to selling stockholders.
  • Decoy20 clinical programs fully discontinued; no active clinical development programs.
  • Auditor's report includes a going-concern explanatory paragraph.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access